Over the past several years, immunotherapy has revolutionized our approach to hematologic malignancies and given new hope in particular to patients with multiple myeloma. In this session we will review the characteristics of major classes of immunotherapy for multiple myeloma, including antibody therapy, CAR T cells, bispecific T Cell engagers and antibody drug conjugates. We will also review the available clinical data on efficacy, duration of response and toxicity. Finally we will discuss the unmet needs in this space, as this therapy is still not curative. We will explore new avenues, including cell culture, cell engineering and patient selection, that are being explored to enhance the success of this promising therapy.